HIFs, angiogenesis, and metabolism: Elusive enemies in breast cancer

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer

Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239 · see citing works

Comprehensive molecular portraits of human breast tumours

The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129 · see citing works

Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

Biomarkers Definitions Working Group (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,771 · see citing works

Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.

Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212 · see citing works

Molecular mechanisms and clinical applications of angiogenesis

Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · see citing works

Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients

Locatelli, F., Fishbane, S. N., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,834 · see citing works

HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia

Kim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905 · see citing works

Otto Warburg's contributions to current concepts of cancer metabolism

Koppenol, W. H., Bounds, P. L., & Dang, C. V. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3038 · Cited by 3,427 · see citing works

Breast cancer statistics, 2019

Desantis, C. E., Ma, J., Gaudet, M. M., Newman, L. A., Miller, K. D., Sauer, A. G., Jemal, A., & Siegel, R. L. (2019) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21583 · Cited by 3,126 · see citing works

From Krebs to clinic: glutamine metabolism to cancer therapy

Altman, B. J., Stine, Z. E., & Dang, C. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.71 · Cited by 2,119 · see citing works

The multifaceted roles of fatty acid synthesis in cancer

Röhrig, F., & Schulze, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.89 · Cited by 1,651 · see citing works

HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations

Semenza, G. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67230 · Cited by 1,335 · see citing works

Hypoxia-inducible expression of tumor-associated carbonic anhydrases.

Wykoff, C. C., Beasley, N. J. P., Watson, P. H., Turner, K., Pastorek, J., Sibtain, A., Wilson, G. D., Turley, H., Talks, K., Maxwell, P. H., et al. (2000) · PubMed · Cited by 1,258 · see citing works

HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression

Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3995-4004.2001 · Cited by 1,256 · cited 1× · see citing works

Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements.

Vaupel, P. W., Schlenger, K., Knoop, C., & Höckel, M. (1991) · PubMed · Cited by 952 · see citing works

Advances in Hypoxia-Inducible Factor Biology

Choudhry, H., & Harris, A. L. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.10.005 · Cited by 873 · see citing works

Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming

Tian, L., Goldstein, A., Wang, H., Ching Lo, H., Sun Kim, I., Welte, T., Sheng, K., Dobrolecki, L. E., Zhang, X., Putluri, N., et al. (2017) · Nature · doi:10.1038/nature21724 · Cited by 841 · see citing works

Antiangiogenic therapy in oncology: current status and future directions

Jayson, G. C., Kerbel, R. S., Ellis, L. M., & Harris, A. L. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01088-0 · Cited by 829 · see citing works

Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9679 · Cited by 820 · see citing works

XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway

Chen, X., Iliopoulos, D., Zhang, Q. H., Tang, Q., Greenblatt, M. B., Hatziapostolou, M., Lim, E., Tam, W. L., Ni, M., Chen, Y., et al. (2014) · Nature · doi:10.1038/nature13119 · Cited by 817 · see citing works

Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells

Chen, F., Chen, J., Yang, L., Liu, J., Zhang, X., Zhang, Y., Tu, Q., Yin, D., Lin, D., Wong, P., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0299-0 · Cited by 712 · see citing works

Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer

Wigerup, C., Påhlman, S., & Bexell, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.009 · Cited by 687 · see citing works

Monocarboxylate transporters in cancer

Payen, V. L., Mina, E., Hée, V. F. V., Porporato, P. E., & Sonveaux, P. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.07.006 · Cited by 665 · see citing works

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa

Khan, K. A., & Kerbel, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.9 · Cited by 661 · see citing works

MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation

Lee, K., Giltnane, J. M., Balko, J. M., Schwarz, L. J., Zotano, Á. G., Hutchinson, K. E., Nixon, M. J., Estrada, M. V., Sanchez, V. M., Sanders, M. E., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.09.009 · Cited by 652 · see citing works

Molecular mechanisms linking exercise to cancer prevention and treatment

Hojman, P., Gehl, J., Christensen, J. F., & Pedersen, B. K. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.09.015 · Cited by 600 · see citing works

Consensus guidelines for the use and interpretation of angiogenesis assays

Nowak-Sliwinska, P. M., Alitalo, K. K., Allen, E., Anisimov, A., Aplin, A. C., Auerbach, R., Augustin, H. G., Bates, D. O., B, J. R. V. B., Bender, R. H. F., et al. (2018) · Angiogenesis · doi:10.1007/s10456-018-9613-x · Cited by 600 · see citing works

Levels of Hypoxia-Inducible Factor-1 During Breast Carcinogenesis

Bos, R., Zhong, H., Hanrahan, C. F., Mommers, E. C. M., Semenza, G. L., Pinedo, H. M., Abeloff, M. D., Simons, J. W., van Diest, P. J., & van der Wall, E. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.309 · Cited by 593 · see citing works

GDF15 mediates the effects of metformin on body weight and energy balance

Coll, A. P., Chen, M., Taskar, P., Rimmington, D., Patel, S., Tadross, J. A., Cimino, I., Yang, M., Welsh, P., Virtue, S., et al. (2020) · Nature · doi:10.1038/s41586-019-1911-y · Cited by 584 · see citing works

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

Schmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassará, A., Wyser Rmili, C., Kiialainen, A., Kienast, Y., Mueller, H.-J., Ooi, C.-H., Laoui, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9670 · Cited by 582 · see citing works

The Regulation and Function of Lactate Dehydrogenase A: Therapeutic Potential in Brain Tumor

Valvona, C. J., Fillmore, H. L., Nunn, P. B., & Pilkington, G. J. (2015) · Brain Pathology · doi:10.1111/bpa.12299 · Cited by 570 · see citing works

The hypoxic tumor microenvironment: A driving force for breast cancer progression

Semenza, G. L. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.05.036 · Cited by 535 · see citing works

Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges

Martin, J. D., Seano, G., & Jain, R. K. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114700 · Cited by 530 · see citing works

An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression

Palazon, A., Tyrakis, P. A., Macias, D., Veliça, P., Rundqvist, H., Fitzpatrick, S., Vojnovic, N., Phan, A. T., Loman, N., Hedenfalk, I., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.003 · Cited by 521 · see citing works

Fasting and cancer: molecular mechanisms and clinical application

Nencioni, A., Caffa, I., Cortellino, S., & Longo, V. D. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0061-0 · Cited by 518 · see citing works

Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment.

Pastorek, J., Pastoreková, S., Callebaut, I., Mornon, J., Zelnı́k, V., Opavský, R., Zaťovičová, M., Liao, S., Portetelle, D., & Stanbridge, E. J. (1994) · PubMed · Cited by 509 · see citing works

Levels of hypoxia‐inducible factor‐1α independently predict prognosis in patients with lymph node negative breast carcinoma

Bos, R., van der Groep, P., Greijer, A. E., Shvarts, A., Meijer, S., Pinedo, H. M., Semenza, G. L., van Diest, P. J., & van der Wall, E. (2003) · Cancer · doi:10.1002/cncr.11246 · Cited by 500 · see citing works

Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models

Schulte, M. L., Fu, A., Zhao, P., Li, J., Geng, L., Smith, S. T., Kondo, J., Coffey, R. J., Johnson, M. O., Rathmell, J. C., et al. (2018) · Nature Medicine · doi:10.1038/nm.4464 · Cited by 494 · see citing works

Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis

Wang, T., Gilkes, D. M., Takano, N., Xiang, L., Luo, W., Bishop, C. J., Chaturvedi, P., Green, J. J., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410041111 · Cited by 493 · see citing works

Interplay between Circadian Clock and Cancer: New Frontiers for Cancer Treatment

Sulli, G., Lam, M. T. Y., & Panda, S. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.07.002 · Cited by 484 · see citing works

Microvessel Density as a Prognostic Factor in Women with Breast Cancer

Uzzan, B., Nicolas, P., Cucherat, M., & Perret, G. Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1957 · Cited by 470 · see citing works

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

Frentzas, S., Simoneau, È., Bridgeman, V. L., Vermeulen, P., Foo, S., Kostaras, E., Nathan, M. R., Wotherspoon, A. C., Gao, Z., Shi, Y., et al. (2016) · Nature Medicine · doi:10.1038/nm.4197 · Cited by 456 · see citing works

Serine Catabolism Regulates Mitochondrial Redox Control during Hypoxia

Ye, J., Fan, J., Venneti, S., Wan, Y.-W., Pawel, B. R., Zhang, J., Finley, L. W. S., Lu, C., Lindsten, T., Cross, J. R., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0250 · Cited by 452 · see citing works

A Variant of SLC1A5 Is a Mitochondrial Glutamine Transporter for Metabolic Reprogramming in Cancer Cells

Yoo, H. C., Park, S. J., Nam, M., Kang, J., Kim, K., Yeo, J. H., Kim, J.-K., Heo, Y., Lee, H. S., Lee, M. Y., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.020 · Cited by 449 · see citing works

Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma

Chia, S., Wykoff, C. C., Watson, P. H., Han, C., Leek, R., Pastorek, J., Gatter, K. C., Ratcliffe, P. J., & Harris, A. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3660 · Cited by 434 · see citing works

The Clinical Importance of Assessing Tumor Hypoxia: Relationship of Tumor Hypoxia to Prognosis and Therapeutic Opportunities

Walsh, J. C., Lebedev, A. Y., Aten, E., Madsen, K. S., Marciano, L., & Kolb, H. C. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5378 · Cited by 419 · see citing works

Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells

Benjamin, D., Robay, D., Hindupur, S. K., Pohlmann, J., Colombi, M., El‐Shemerly, M., Maira, S.-M., Moroni, C., Lane, H. A., & Hall, M. N. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.043 · Cited by 414 · see citing works

Dietary modifications for enhanced cancer therapy

Kanarek, N., Petrova, B., & Sabatini, D. M. (2020) · Nature · doi:10.1038/s41586-020-2124-0 · Cited by 414 · see citing works

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Formisano, L., Lu, Y., Servetto, A., Hanker, A. B., Jansen, V. M., Bauer, J. A., Sudhan, D. R., Zotano, Á. G., Croessmann, S., Guo, Y. P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09068-2 · Cited by 409 · see citing works

Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1

Rolfs, A., Kvietikova, I., Gassmann, M., & Wenger, R. H. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.32.20055 · Cited by 401 · see citing works

Untitled work

(2002) · PubMed · Cited by 385 · see citing works

Hypoxia‐inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype

Semenza, G. L. (2016) · The EMBO Journal · doi:10.15252/embj.201695204 · Cited by 369 · see citing works

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

Gebhart, G., Lamberts, L. E., Wimana, Z., Garcia, C. A., Emonts, P., Ameye, L., Stroobants, S. G., Huizing, M. T., Aftimos, P., Tol, J., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv577 · Cited by 354 · see citing works

Metabolism of [U‐ ¹³ C]glucose in human brain tumors <i>in vivo</i>

Maher, E. A., Marin‐Valencia, I., Bachoo, R. M., Mashimo, T., Raisanen, J., Hatanpaa, K. J., Jindal, A., Jeffrey, F. M., Choi, C., Madden, C., et al. (2012) · NMR in Biomedicine · doi:10.1002/nbm.2794 · Cited by 341 · see citing works

ERGO: A pilot study of ketogenic diet in recurrent glioblastoma

Rieger, J., Bähr, O., Maurer, G. D., Hattingen, E., Franz, K., Brucker, D. P., Walenta, S., Kämmerer, U., Coy, J. F., Weller, M., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2382 · Cited by 283 · see citing works

Collagen prolyl 4-hydroxylase 1 is essential for HIF-1α stabilization and TNBC chemoresistance

Xiong, G., Stewart, R. L., Chen, J., Gao, T., Scott, T. L., Samayoa, L. M., O’Connor, K. L., Lane, A. N., & Xu, R. (2018) · Nature Communications · doi:10.1038/s41467-018-06893-9 · Cited by 277 · see citing works

Fate-mapping post-hypoxic tumor cells reveals a ROS-resistant phenotype that promotes metastasis

Godet, I., Shin, Y. J., Ju, J. A., Ye, I. C., Wang, G., & Gilkes, D. M. (2019) · Nature Communications · doi:10.1038/s41467-019-12412-1 · Cited by 274 · see citing works

Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype

Lu, H., Samanta, D., Xiang, L., Zhang, H., Hu, H., Chen, I., Bullen, J. W., & Semenza, G. L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513433112 · Cited by 270 · see citing works

A guide to 13C metabolic flux analysis for the cancer biologist

Antoniewicz, M. R. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0060-y · Cited by 264 · see citing works

The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study

de Groot, S., Vreeswijk, M. P. G., Welters, M. J. P., Gravesteijn, G., Boei, J. J. W. A., Jochems, A., Houtsma, D., Putter, H., van der Hoeven, J. J. M., Nortier, J. W. R., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1663-5 · Cited by 257 · see citing works

Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy

Ye, Y., Hu, Q., Chen, H., Liang, K., Yuan, Y., Xiang, Y., Ruan, H., Zhang, Z., Song, A., Zhang, H., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0045-8 · Cited by 251 · see citing works

Hypoxia-Inducible Factor-1α Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer

Generali, D., Berruti, A., Brizzi, M. P., Campo, L., Bonardi, S., Wigfield, S., Bersiga, A., Allevi, G., Milani, M., Aguggini, S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2690 · Cited by 250 · see citing works

Expression of the Hypoxia-Inducible and Tumor-Associated Carbonic Anhydrases in Ductal Carcinoma in Situ of the Breast

Wykoff, C. C., Beasley, N. J. P., Watson, P. H., Campo, L., Chia, S., English, R. E., Pastorek, J., Sly, W. S., Ratcliffe, P. J., & Harris, A. L. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64048-5 · Cited by 249 · see citing works

Increased Serine Synthesis Provides an Advantage for Tumors Arising in Tissues Where Serine Levels Are Limiting

Sullivan, M. R., Mattaini, K. R., Dennstedt, E. A., Nguyen, A. A., Sivanand, S., Reilly, M. F., Meeth, K. M., Muir, A., Darnell, A. M., Bosenberg, M., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.015 · Cited by 242 · see citing works

ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer

van Geldermalsen, M., Wang, Q., Nagarajah, R., Marshall, A., Thoeng, A., Gao, D., Ritchie, W., Feng, Y., Bailey, C. G., Deng, N., et al. (2015) · Oncogene · doi:10.1038/onc.2015.381 · Cited by 235 · see citing works

Regulation of Glutamine Carrier Proteins by RNF5 Determines Breast Cancer Response to ER Stress-Inducing Chemotherapies

Jeon, Y. J., Khelifa, S., Ratnikov, B. I., Scott, D. A., Feng, Y., Parisi, F., Ruller, C. M., Lau, E. K., Kim, H., Brill, L. M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.006 · Cited by 229 · see citing works

Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine

Briggs, K. J., Koivunen, P., Cao, S., Backus, K. M., Olenchock, B. A., Patel, H., Zhang, Q. H., Signoretti, S., Gerfen, G. J., Richardson, A. L., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.042 · Cited by 228 · see citing works

MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4

Hong, C. S., Graham, N. A., Gu, W., Camacho, C. E., Mah, V. H., Maresh, E. L., Alavi, M., Bagryanova, L., Krotee, P., Gardner, B. K., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.057 · Cited by 223 · see citing works

Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2

Incio, J., Ligibel, J. A., McManus, D. T., Suboj, P., Jung, K., Kawaguchi, K., Pinter, M., Babykutty, S., Chin, S. M., Vardam, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0945 · Cited by 222 · see citing works

Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia

Stessels, F., den Eynden, G. V., der Auwera, I. V., Salgado, R., den Heuvel, E. V., Harris, A. L., Jackson, D. G., Colpaert, C., Marck, E. A. V., Dirix, L. Y., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601727 · Cited by 215 · see citing works

HIF2α Acts as an mTORC1 Activator through the Amino Acid Carrier SLC7A5

Elorza, A., Soro-Arnáiz, I., Meléndez‐Rodríguez, F., Rodríguez-Vaello, V., Marsboom, G., de Cárcer, G., Acosta‐Iborra, B., Albacete-Albacete, L., Ordóñez, Á., Serrano‐Oviedo, L., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.09.017 · Cited by 206 · see citing works

Hypoxic Radioresistance: Can ROS Be the Key to Overcome It?

Wang, H., Jiang, H., Gucht, M. V. D., & Ridder, M. D. (2019) · Cancers · doi:10.3390/cancers11010112 · Cited by 206 · see citing works

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

Barrios, C. H., Liu, M.-C., Lee, S. C., Vanlemmens, L., Ferrero, J.-­., Tabei, T., Pivot, X. B., Iwata, H., Aogi, K., Lugo-Quintana, R., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0788-0 · Cited by 199 · see citing works

Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies

Mayer, E. L., & Krop, I. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1834 · Cited by 197 · see citing works

Inherent DNA‐binding specificities of the HIF‐1α and HIF‐2α transcription factors in chromatin

Smythies, J. A., Sun, M., Masson, N., Salama, R., Simpson, P. D., Murray, E., Neumann, V., Cockman, M. E., Choudhry, H., Ratcliffe, P. J., et al. (2019) · The EMBO Reports · doi:10.15252/embr.201846401 · Cited by 195 · see citing works

A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer

Mihály, Z., Kormos, M., Lánczky, A., Dank, M., Budczies, J., Szász, M. A., & Győrffy, B. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2622-y · Cited by 190 · see citing works

ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models

Brooks, D. L. P., Schwab, L. P., Krutilina, R. I., Parke, D. N., Sethuraman, A., Hoogewijs, D., Schörg, A., Gotwald, L., Fan, M., Wenger, R. H., et al. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0510-x · Cited by 190 · see citing works

Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors

Samanta, D., & Semenza, G. L. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.07.002 · Cited by 190 · see citing works

Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer

Sutendra, G., Dromparis, P., Kinnaird, A. S., Stenson, T. H., Haromy, A., Parker, J. M. R., McMurtry, M. S., & Michelakis, E. D. (2012) · Oncogene · doi:10.1038/onc.2012.198 · Cited by 185 · see citing works

HIF2-Induced Long Noncoding RNA RAB11B-AS1 Promotes Hypoxia-Mediated Angiogenesis and Breast Cancer Metastasis

Niu, Y.-L., Bao, L., Chen, Y., Wang, C., Luo, M., Zhang, B., Zhou, M., Wang, J. E., Fang, Y. V., Kumar, A., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1532 · Cited by 177 · see citing works

ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis

Chen, Y., Zhang, B., Bao, L., Jin, L., Yang, M., Peng, Y., Kumar, A., Wang, J. E., Wang, C., Zou, X., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95089 · Cited by 176 · see citing works

Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer

Wang, B.-Y., Zhang, J., Wang, J.-L., Sun, S., Wang, Z., Wang, L.-P., Zhang, Q.-L., Lv, F.-F., Cao, E.-Y., Shao, Z.-M., et al. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0194-x · Cited by 174 · see citing works

The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis

Yu, M., Yongzhi, H., Chen, S., Luo, X., Lin, Y., Zhou, Y., Jin, H., Hou, B., Deng, Y., Tu, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17445 · Cited by 167 · see citing works

Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition

Lampa, M., Arlt, H., He, T., Ospina, B., Reeves, J., Zhang, B., Murtie, J. C., Deng, G., Barberis, C., Hoffmann, D., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185092 · Cited by 166 · see citing works

Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically

Chafe, S. C., McDonald, P. C., Saberi, S., Nemirovsky, O., Venkateswaran, G., Burugu, S., Gao, D., Delaidelli, A., Kyle, A. H., Baker, J. H. E., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0657 · Cited by 166 · see citing works

A Ketogenic Diet Reduces Central Obesity and Serum Insulin in Women with Ovarian or Endometrial Cancer

Cohen, C. W., Fontaine, K. R., Arend, R. C., Alvarez, R. D., Leath, C. A., Huh, W. K., Bevis, K. S., Kim, K. H., Straughn, J. M., & Gower, B. A. (2018) · Journal of Nutrition · doi:10.1093/jn/nxy119 · Cited by 164 · see citing works

FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer

Fu, X., Pereira, R., Angelis, C. D., Veeraraghavan, J., Nanda, S., Qin, L., Cataldo, M. L., Sethunath, V., Mehravaran, S., Gutiérrez, C., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911584116 · Cited by 163 · see citing works

18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO

Gebhart, G., Cenzano, C. G., Holmes, E. M., Robles, J., Garcia, C. A., Cortés, M., de Azambuja, E., Fauria, K., Dooren, V. V., Aktan, G., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.119271 · Cited by 162 · see citing works

Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype

Garcia, S., Dalès, J.-P., Charafe‐Jauffret, E., Carpentier-Meunier, S., Andrac, L., Jacquemier, J. D., Andonian, C., Lavaut, M., Allasia, C., Bonnier, P., et al. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.11.015 · Cited by 156 · see citing works

Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis

van Kuijk, S. J. A., Yaromina, A., Houben, R. M. A., Niemans, R., Lambin, P., & Dubois, L. J. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00069 · Cited by 154 · see citing works

Hypoxia induces miR-153 through the IRE1α-XBP1 pathway to fine tune the HIF1α/VEGFA axis in breast cancer angiogenesis

Liang, H., Xiao, J., Zhou, Z., Wu, J., Ge, F., Li, Z., Zhang, H., Sun, J., Li, F., Liu, R., et al. (2018) · Oncogene · doi:10.1038/s41388-017-0089-8 · Cited by 154 · see citing works

Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade

Li, Q., Wang, Y., Jia, W., Deng, H., Li, G., Deng, W., Chen, J., Kim, B. Y. S., Jiang, W., Liu, Q., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2179 · Cited by 154 · see citing works

Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH)

Rai, G., Brimacombe, K. R., Mott, B. T., Urban, D. J., Hu, X., Yang, S., Lee, T. D., Cheff, D. M., Kouznetsova, J., Benavides, G. A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00941 · Cited by 153 · see citing works

Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial

Coudert, B. P., Pierga, J., Mouret‐Reynier, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70475-9 · Cited by 149 · see citing works

Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration

Beloueche‐Babari, M., Galobart, T. C., Delgado‐Goñi, T., Wantuch, S., Parkes, H. G., Tandy, D., Harker, J. A., & Leach, M. O. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0717-x · Cited by 148 · see citing works

Estrogen receptor-α directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer

Yang, J., AlTahan, A. M., Jones, D. T., Buffa, F. M., Bridges, E., Interiano, R. B., Qu, C., Vogt, N., Li, J., Baban, D. F., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1422015112 · Cited by 139 · see citing works

Metformin Inhibits Metastatic Breast Cancer Progression and Improves Chemosensitivity by Inducing Vessel Normalization via PDGF-B Downregulation

Wang, J.-C., Li, G.-Y., Wang, B., Han, S.-X., Sun, X., Jiang, Y.-N., Shen, Y.-W., Zhou, C., Feng, J., Lu, S.-Y., et al. (2019) · Journal of Experimental &amp; Clinical Cancer Research · doi:10.1186/s13046-019-1211-2 · Cited by 138 · see citing works

A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors

Chu, Q. S.-C., Sangha, R. S., Spratlin, J. L., Vos, L. J., Mackey, J. R., McEwan, A. J. B., Venner, P. M., & Michelakis, E. D. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0221-y · Cited by 137 · see citing works

Hypoxia-Inducible Factor-2α Correlates to Distant Recurrence and Poor Outcome in Invasive Breast Cancer

Helczynska, K., Larsson, A.-M., Holmquist Mengelbier, L., Bridges, E., Fredlund, E., Borgquist, S., Landberg, G., Påhlman, S., & Jirström, K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1135 · Cited by 136 · see citing works

The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours

Ansari, R. E., Craze, M. L., Miligy, I. M., Diez, M., Nolan, C. C., Ellis, I. O., Rakha, E. A., & Green, A. R. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0946-6 · Cited by 136 · see citing works

Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging

Tromberg, B. J., Zhang, Z., Leproux, A., O’Sullivan, T. D., Cerussi, A. E., Carpenter, P. M., Mehta, R. S., Roblyer, D. M., Yang, W. T., Paulsen, K. D., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0346 · Cited by 132 · see citing works

Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer

Lord, S., Cheng, W., Liu, D., Gaude, E., Haider, S. A., Metcalf, T., Patel, N., Teoh, E., Gleeson, F. V., Bradley, K. M., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.08.021 · Cited by 132 · see citing works

Decylubiquinone suppresses breast cancer growth and metastasis by inhibiting angiogenesis via the ROS/p53/ BAI1 signaling pathway

Cao, J., Liu, X., Yang, Y., et al. (2020) · Angiogenesis · doi:10.1007/s10456-020-09707-z · Cited by 132 · see citing works

Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer

Morotti, M., Bridges, E., Valli, A., Choudhry, H., Sheldon, H., Wigfield, S., Gray, N., Zois, C. E., Grimm, F., Jones, D., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818521116 · Cited by 131 · see citing works

Hypoxia-induced carbonic anhydrase IX facilitates lactate flux in human breast cancer cells by non-catalytic function

Jamali, S., Klier, M., Ames, S., Barros, L. F., McKENNA, R. V., Deitmer, J. W., & Becker, H. M. (2015) · Scientific Reports · doi:10.1038/srep13605 · Cited by 129 · see citing works

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

Miles, D. W., Cameron, D., Bondarenko, I., Manzyuk, L., Alcedo, J. C., Lopez, R. I., Im, S., Canon, J.-L. R., Shparyk, Y. V., Yardley, D. A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.09.024 · Cited by 126 · see citing works

Reduced Expression of Hypoxia-Inducible Factor-1α in Perinecrotic Regions of Solid Tumors

Sobhanifar, S., Aquino‐Parsons, C., Stanbridge, E. J., & Olive, P. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4480 · Cited by 124 · see citing works

Obesity-associated inflammation promotes angiogenesis and breast cancer via angiopoietin-like 4

Kolb, R. H., Kluz, P., Tan, Z. W., Borcherding, N. C., Bormann, N. L., Vishwakarma, A., Balcziak, L. K., Zhu, P., Davies, B. S. J., Gourronc, F. A., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0592-6 · Cited by 123 · see citing works

Up-regulation of glyceraldehyde-3-phosphate dehydrogenase gene expression by HIF-1 activity depending on Sp1 in hypoxic breast cancer cells

Higashimura, Y., Nakajima, Y., Yamaji, R., et al. (2011) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2011.02.011 · Cited by 122 · see citing works

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients

Tolaney, S. M., Ziehr, D. R., Guo, H., Ng, M. R., Barry, W. T., Higgins, M. J., Isakoff, S. J., Brock, J. E., Ivanova, E. V., Paweletz, C. P., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0229 · Cited by 118 · see citing works

LDH-A regulates the tumor microenvironment via HIF-signaling and modulates the immune response

Serganova, I. S., Cohen, I., Vemuri, K., Shindo, M., Maeda, M., Mane, M. M., Moroz, E., Khanin, R., Satagopan, J. M., Koutcher, J. A., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0203965 · Cited by 118 · see citing works

Mammostrat®as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy

Bartlett, J. M. S., Thomas, J. S. J., Ross, D. T., Seitz, R. S., Ring, B. Z., Beck, R. A., Pedersen, H. C., Munro, A. F., Kunkler, I. H., Campbell, F., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2604 · Cited by 117 · see citing works

Phosphorylated ERα, HIF-1α, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast Cancer

Generali, D., Buffa, F. M., Berruti, A., Brizzi, M. P., Campo, L., Bonardi, S., Bersiga, A., Allevi, G., Milani, M., Aguggini, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.7083 · Cited by 116 · see citing works

18F-Fluoromisonidazole PET/CT: A Potential Tool for Predicting Primary Endocrine Therapy Resistance in Breast Cancer

Cheng, J., Li, L., Xu, J., Sun, Y., Zhang, Y., Wang, X., Pan, L., Shao, Z., Zhang, Y., & Liu, G. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.111963 · Cited by 107 · see citing works

Bevacizumab Induces Acute Hypoxia and Cancer Progression in Patients with Refractory Breast Cancer: Multimodal Functional Imaging and Multiplex Cytokine Analysis

Ueda, S., Saeki, T., Osaki, A., Yamane, T., & Kuji, I. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0874 · Cited by 104 · see citing works

Lipogenetic and glycolytic enzyme activities in carcinoma and nonmalignant diseases of the human breast

Szutowicz, A., Kwiatkowski, J., & Angielski, S. (1979) · British Journal of Cancer · doi:10.1038/bjc.1979.120 · Cited by 103 · see citing works

NDRG1 regulates neutral lipid metabolism in breast cancer cells

Sevinsky, C. J., Khan, F., Kokabee, L., Darehshouri, A., Maddipati, K. R., & Conklin, D. S. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0980-4 · Cited by 103 · see citing works

Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer

Lukey, M. J., Cluntun, A. A., Katt, W. P., Lin, M.-C. J., Druso, J. E., Ramachandran, S., Erickson, J. W., Le, H. H., Wang, Z.-E., Blank, B., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.076 · Cited by 103 · see citing works

Ablation of the ASCT2 (SLC1A5) gene encoding a neutral amino acid transporter reveals transporter plasticity and redundancy in cancer cells

Bröer, A., Gauthier-Coles, G., Rahimi, F., van Geldermalsen, M., Dorsch, D., Wegener, A. A., Holst, J., & Bröer, S. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006378 · Cited by 101 · see citing works

Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy

Bane, A. L., Whelan, T. J., Pond, G. R., Parpia, S., Gohla, G., Fyles, A., Pignol, J., Pritchard, K. I., Chambers, S., & Levine, M. N. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu090 · Cited by 100 · see citing works

Human CHCHD4 mitochondrial proteins regulate cellular oxygen consumption rate and metabolism and provide a critical role in hypoxia signaling and tumor progression

Yang, J., Staples, O. D., Thomas, L. W., Briston, T., Robson, M. P., Poon, E., Simões, M. L., El‐Emir, E., Buffa, F. M., Ahmed, A., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58780 · Cited by 95 · see citing works

Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes

Ye, I. C., Fertig, E. J., DiGiacomo, J. W., Considine, M., Godet, I., & Gilkes, D. M. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0345 · Cited by 95 · see citing works

Prognostic role of glycolysis for cancer outcome: evidence from 86 studies

Yu, M., Chen, S., Hong, W., Gu, Y., Huang, B., Lin, Y., Zhou, Y., Jin, H., Deng, Y., Tu, L., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02847-w · Cited by 93 · see citing works

Noninvasive Detection of Breast Cancer Lymph Node Metastasis Using Carbonic Anhydrases IX and XII Targeted Imaging Probes

Tafreshi, N. K., Bui, M. M., Bishop, K., Lloyd, M. C., Enkemann, S. A., Lopez, A. S., Abrahams, D. F., Carter, B. W., Vágner, J., Grobmyer, S. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0238 · Cited by 91 · see citing works

Metabolism-Related Proteins Are Differentially Expressed according to the Molecular Subtype of Invasive Breast Cancer Defined by Surrogate Immunohistochemistry

Choi, J., Jung, W.-H., & Koo, J. S. (2012) · Pathobiology · doi:10.1159/000339513 · Cited by 89 · see citing works

The SIAH2-NRF1 axis spatially regulates tumor microenvironment remodeling for tumor progression

Ma, B., Cheng, H., Mu, C., Geng, G., Zhao, T., Luo, Q., Ma, K., Chang, R., Liu, Q., Gao, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08618-y · Cited by 89 · see citing works

Pan-genomic binding of hypoxia-inducible transcription factors

Schödel, J., Mole, D. R., & Ratcliffe, P. J. (2013) · Biological Chemistry · doi:10.1515/hsz-2012-0351 · Cited by 86 · see citing works

The accuracy of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review

Tian, F., Shen, G., Deng, Y., et al. (2017) · European Radiology · doi:10.1007/s00330-017-4831-y · Cited by 85 · see citing works

Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells

Chen, Z., Wang, Y.-Z., Warden, C., & Chen, S. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.02.004 · Cited by 81 · see citing works

c- erb B-2 Related Aggressiveness in Breast Cancer Is Hypoxia Inducible Factor-1α Dependent

Giatromanolaki, A. N., Koukourakis, M. I., Simopoulos, C., Polychronidis, A., Gatter, K. C., Harris, A. L., & Sivridis, E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1068 · Cited by 81 · see citing works

Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer

Samuel, S., Varghese, E., Kubatka, P., Triggle, C., & Büsselberg, D. (2019) · Biomolecules · doi:10.3390/biom9120846 · Cited by 81 · see citing works

Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases

Yan, S., Jiao, X., Zou, H., & Li, K. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0296-y · Cited by 80 · see citing works

Definition of a Novel Feed-Forward Mechanism for Glycolysis-HIF1α Signaling in Hypoxic Tumors Highlights Aldolase A as a Therapeutic Target

Grandjean, G. V., de Jong, P. R., James, B. P., Koh, M. Y., Lemos, R., Kingston, J., Aleshin, A. E., Bankston, L. A., Miller, C. P., Cho, E. J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0401 · Cited by 79 · see citing works

The action of β-hydroxybutyrate on the growth, metabolism and global histone H3 acetylation of spontaneous mouse mammary tumours: evidence of a β-hydroxybutyrate paradox

Rodrigues, L. M., Uribe‐Lewis, S., Madhu, B., Honess, D. J., Stubbs, M., & Griffiths, J. R. (2017) · Cancer & Metabolism · doi:10.1186/s40170-017-0166-z · Cited by 78 · see citing works

Repositioning Proton Pump Inhibitors as Anticancer Drugs by Targeting the Thioesterase Domain of Human Fatty Acid Synthase

Fako, V. E., Wu, X., Pflug, B. R., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501543u · Cited by 76 · see citing works

Ketogenic diets in medical oncology: a systematic review with focus on clinical outcomes

Klement, R. J., Brehm, N., & Sweeney, R. A. (2020) · Medical Oncology · doi:10.1007/s12032-020-1337-2 · Cited by 76 · see citing works

EglN2 associates with the NRF1‐PGC1α complex and controls mitochondrial function in breast cancer

Zhang, J., Wang, C., Chen, X., Takada, M., Fan, C., Zheng, X., Wen, H., Liu, Y., Wang, C., Pestell, R. G., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201591437 · Cited by 74 · see citing works

HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer

Jarman, E. J., Ward, C., Turnbull, A., Martínez-Pérez, C., Meehan, J., Xintaropoulou, C., Sims, A. H., & Langdon, S. P. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1097-0 · Cited by 73 · see citing works

Targeting tumor-associated acidity in cancer immunotherapy

Lacroix, R., Rozeman, E. A., Kreutz, M. P., Renner, K., & Blank, C. U. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2195-z · Cited by 71 · see citing works

Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy

(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2018.11.001 · Cited by 71 · see citing works

Expression of HIF-1α is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer

Jögi, A., Ehinger, A., Hartman, L. W., & Alkner, S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226150 · Cited by 70 · see citing works

Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer

Demas, D. M., Demo, S. D., Fallah, Y., Clarke, R. C., Nephew, K. P., Althouse, S. K., Sandusky, G. E., He, W., & Shajahan‐Haq, A. N. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00686 · Cited by 66 · see citing works

Hypoxia-reprogrammed tricarboxylic acid cycle promotes the growth of human breast tumorigenic cells

Tang, K., Yu, Y., Zhu, L., Xu, P., Chen, J., Ma, J., Zhang, H., Fang, H., Sun, W., Zhou, L., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0932-1 · Cited by 66 · see citing works

Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy

Nieto, Y. L., Woods, J., Nawaz, F., Baron, A. D., Jones, R. B., Shpall, E. J., & Nawaz, S. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603875 · Cited by 63 · see citing works

Benzylserine inhibits breast cancer cell growth by disrupting intracellular amino acid homeostasis and triggering amino acid response pathways

van Geldermalsen, M., Quek, L., Turner, N. A., Freidman, N., Pang, A., Guan, Y. F., Krycer, J. R., Ryan, R. M., Wang, Q., & Holst, J. (2018) · BMC Cancer · doi:10.1186/s12885-018-4599-8 · Cited by 62 · see citing works

Targeting SLC25A10 alleviates improved antioxidant capacity and associated radioresistance of cancer cells induced by chronic-cycling hypoxia

Hlouschek, J., Ritter, V., Wirsdörfer, F., Klein, D., Jendrossek, V., & Matschke, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.09.002 · Cited by 62 · see citing works

The proteoglycan-like domain of carbonic anhydrase IX mediates non-catalytic facilitation of lactate transport in cancer cells

Ames, S., Pastoreková, S., & Becker, H. M. (2018) · Oncotarget · doi:10.18632/oncotarget.25371 · Cited by 61 · see citing works

Hypoxic pathobiology of breast cancer metastasis

Schito, L., & Rey, S. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.05.004 · Cited by 60 · see citing works

Breast cancers utilize hypoxic glycogen stores via PYGB, the brain isoform of glycogen phosphorylase, to promote metastatic phenotypes

Altemus, M., Goo, L., Little, A. C., Yates, J. A., Cheriyan, H., Wu, Z.-F., & Merajver, S. D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220973 · Cited by 59 · see citing works

CAIX forms a transport metabolon with monocarboxylate transporters in human breast cancer cells

Ames, S., Andring, J. T., McKENNA, R. V., & Becker, H. M. (2019) · Oncogene · doi:10.1038/s41388-019-1098-6 · Cited by 58 · see citing works

Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer

den Eynden, G. G. V., der Auwera, I. V., Laere, S. V., Colpaert, C., Turley, H., Harris, A. L., van Dam, P. A., Dirix, L. Y., Vermeulen, P., & Marck, E. A. V. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602828 · Cited by 56 · see citing works

The Linkage between Breast Cancer, Hypoxia, and Adipose Tissue

Rausch, L. K., Netzer, N. C., Hoegel, J. J., & Pramsohler, S. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00211 · Cited by 56 · see citing works

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study

Dieras, V. C., Wildiers, H. P. M. W., Jassem, J., et al. (2015) · The Breast · doi:10.1016/j.breast.2014.11.003 · Cited by 50 · see citing works

Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer

Reguera-Nuñez, E., Xu, P., Chow, A., Man, S., Hilberg, F., & Kerbel, R. S. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0999-5 · Cited by 50 · see citing works

Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer

Quintela-Fandiño, M., Morales, S. M., Cortés-Salgado, A., Manso, L., Apala, J. V., Muñoz, M., Cudós, A. G., Fortuny, J. S., Gión, M., López‐Alonso, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2023 · Cited by 49 · see citing works

Metformin-induced caveolin-1 expression promotes T-DM1 drug efficacy in breast cancer cells

Chung, Y., Chang, C.-M., Wei, W., Chang, T.-W., Chang, K., & Chao, W. (2018) · Scientific Reports · doi:10.1038/s41598-018-22250-8 · Cited by 48 · see citing works

Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease

Wu, F. T. H., Xu, P., Chow, A., Man, S., Krüger, J., Khan, K. A., Paez-Ribes, M., Pham, E., & Kerbel, R. S. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0297-1 · Cited by 47 · see citing works

Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial

GOUSSIA, A. C., Simou, N., Zagouri, F., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200302 · Cited by 46 · see citing works

The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts

Bello, E., Taraboletti, G., Colella, G., Zucchetti, M., Forestieri, D., Licandro, S. A., Berndt, A., Richter, P., D’Incalci, M., Cavalletti, E., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0275-t · Cited by 45 · see citing works

A network analysis to identify mediators of germline-driven differences in breast cancer prognosis

Escala-Garcia, M., Abraham, J., Andrulis, I. L., Anton‐Culver, H., Arndt, V., Ashworth, A., Auer, P. L., Auvinen, P., Beckmann, M. W., Beesley, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14100-6 · Cited by 42 · see citing works

2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer

Tagg, S., Foster, P., Leese, M. P., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604752 · Cited by 41 · see citing works

DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer

Gampenrieder, S. P., Rinnerthaler, G., Hackl, H., Pulverer, W., Weinhaeusel, A., Ilic, S., Hufnagl, C., Hauser‐Kronberger, C., Egle, A., Risch, A., et al. (2018) · Theranostics · doi:10.7150/thno.23544 · Cited by 41 · see citing works

Na+,HCO3− cotransporter NBCn1 accelerates breast carcinogenesis

Boedtkjer, E. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09784-7 · Cited by 41 · see citing works

Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment

Mehta, S., Hughes, N. P., Li, S., Jubb, A. M., Adams, R. F., Lord, S., Koumakis, L., van Stiphout, R. G. P. M., Padhani, A. R., Makris, A., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.07.017 · Cited by 39 · see citing works

Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer

Golfmann, K., Meder, L., Koker, M., Volz, C., Borchmann, S., Tharun, L., Dietlein, F., Malchers, F., Florin, A., Büttner, R., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0380-3 · Cited by 39 · see citing works

Targeting of two aspects of metabolism in breast cancer treatment

Gang, B. P., Dilda, P. J., Hogg, P. J., & Blackburn, A. C. (2014) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.955992 · Cited by 38 · see citing works

Hypoxia-inducible factor 1-alpha expression correlates with response to neoadjuvant chemotherapy in women with breast cancer

Nie, C., Lv, H., Bie, L., Hou, H., & Chen, X. (2018) · Medicine · doi:10.1097/md.0000000000013551 · Cited by 38 · see citing works

Up-regulation of the kinase gene SGK1 by progesterone activates the AP-1–NDRG1 axis in both PR-positive and -negative breast cancer cells

Godbole, M. S., Togar, T., Patel, K., Dharavath, B., Yadav, N., Janjuha, S., Gardi, N., Tiwary, K., Terwadkar, P., Desai, S., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002894 · Cited by 37 · see citing works

A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases

Leone, J. P., Duda, D. G., Hu, J., Barry, W. T., Trippa, L., Gerstner, E. R., Jain, R. K., Tan, S., Lawler, E., Winer, E. P., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05445-z · Cited by 37 · see citing works

Challenges facing antiangiogenesis therapy: The significant role of hypoxia‐inducible factor and MET in development of resistance to anti‐vascular endothelial growth factor‐targeted therapies

Mahdi, A., Darvishi, B., Majidzadeh‐A, K., Salehi, M., & Farahmand, L. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27414 · Cited by 35 · see citing works

HIF-1α Overexpression in Ductal Carcinoma In Situ of the Breast in BRCA1 and BRCA2 Mutation Carriers

van der Groep, P., van Diest, P. J., Smolders, Y. H. C. M., Ausems, M. G. E. M., van der Luijt, R. B., Menko, F. H., Bart, J., de Vries, E. G. E., & van der Wall, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056055 · Cited by 34 · see citing works

Breast Cancer Blood Flow and Metabolism on Dual-Acquisition 18F-FDG PET: Correlation with Tumor Phenotype and Neoadjuvant Chemotherapy Response

Humbert, O., Lasserre, M., Bertaut, A., Fumoleau, P., Coutant, C., Brunotte, F., & Cochet, A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.203075 · Cited by 33 · see citing works

Intracellular hypoxia measured by 18F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer

Asano, A., Ueda, S., Kuji, I., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0970-6 · Cited by 33 · see citing works

Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1

Chandran, V. I., Månsson, A., Barbachowska, M., Cerezo-Magaña, M., Nodin, B., Joshi, B., Koppada, N., Saad, O. M., Gluz, O., Isaksson, K., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0856 · Cited by 32 · see citing works

Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition

Quintela-Fandiño, M., Apala, J. V., Malón, D., Mouron, S. A., Hornedo, J., González‐Cortijo, L., Colomer, R., & Guerra, J. A. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1152-x · Cited by 30 · see citing works

Predictive role of the overexpression for CXCR4, C-Met, and VEGF-C among breast cancer patients: A meta-analysis

Wang, F., Li, S., Zhao, Y., et al. (2016) · The Breast · doi:10.1016/j.breast.2016.04.016 · Cited by 29 · see citing works

Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours

Jones, R. L., Ratain, M. J., O'Dwyer, P. J., Siu, L. L., Jassem, J., Médioni, J., deJonge, M. J. A., Rudin, C. M., Sawyer, M. B., Khayat, D., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.07.024 · Cited by 29 · see citing works

In vitro downregulated hypoxia transcriptome is associated with poor prognosis in breast cancer

Abu‐Jamous, B., Buffa, F. M., Harris, A. L., & Nandi, A. K. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0673-0 · Cited by 28 · see citing works

BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation

Li, A. G., Murphy, E. C., Culhane, A. C., Powell, E., Wang, H., Bronson, R. T., Von, T., Giobbie‐Hurder, A., Gelman, R. S., Briggs, K. J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1807112115 · Cited by 28 · see citing works

Causes and Consequences of A Glutamine Induced Normoxic HIF1 Activity for the Tumor Metabolism

Kappler, M., Pabst, U., Weinholdt, C., Taubert, H. W., Rot, S., Kaune, T., Kotrba, J., Porsch, M., Güttler, A., Bache, M., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194742 · Cited by 28 · see citing works

The prognostic value of hypoxia-inducible factor-1α in advanced cancer survivors: a meta-analysis with trial sequential analysis

Han, S., Huang, T., Hou, F., Yao, L., Wang, X., & Wu, X. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919875851 · Cited by 28 · see citing works

Insights into Hypoxia: Non-invasive Assessment through Imaging Modalities and Its Application in Breast Cancer

Naranjo, I. D. (2019) · Journal of Breast Cancer · doi:10.4048/jbc.2019.22.e26 · Cited by 27 · see citing works

Estrogen-dependent downregulation of hypoxia-inducible factor (HIF)-2α in invasive breast cancer cells

Fuady, J. H., Gutsche, K., Santambrogio, S., Varga, Z., Hoogewijs, D., & Wenger, R. H. (2016) · Oncotarget · doi:10.18632/oncotarget.8866 · Cited by 26 · see citing works

Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft

Bharti, S. K., Mironchik, Y., Wildes, F. B., Penet, M., Goggins, E. S., Krishnamachary, B., & Bhujwalla, Z. M. (2018) · Oncotarget · doi:10.18632/oncotarget.24569 · Cited by 26 · see citing works

The potential of hypoxia markers as target for breast molecular imaging – a systematic review and meta-analysis of human marker expression

Adams, A. L. L., van Brussel, A. S. A., Vermeulen, J. F., Mali, W. P. T. M., van der Wall, E., van Diest, P. J., & Elias, S. G. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-538 · Cited by 24 · see citing works

Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab)

Ho, D., Huang, J. Y., Chapman, J. W., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4273-x · Cited by 23 · see citing works

CHCHD4 confers metabolic vulnerabilities to tumour cells through its control of the mitochondrial respiratory chain

Thomas, L. W., Stephen, J. M., Esposito, C., et al. (2019) · Cancer & Metabolism · doi:10.1186/s40170-019-0194-y · Cited by 23 · see citing works

Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy

Koukourakis, M. I., Giatromanolaki, A. N., Bottini, A., Cappelletti, M., Zanotti, L., Allevi, G., Strina, C., Ardine, M., Milani, M., Brugnoli, G., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.196 · Cited by 19 · see citing works

CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy

Alves, W. E. F. M., Bonatelli, M., Dufloth, R. M., Kerr, L. M., Carrara, G. F. A., Costa, R. F. A., Scapulatempo‐Neto, C., Tiezzi, D. G., Vieira, R. A. D. C., & Pinheiro, C. M. (2019) · BMC Cancer · doi:10.1186/s12885-019-6353-2 · Cited by 19 · see citing works

A hypoxic signature marks tumors formed by disseminated tumor cells in the BALB-neuT mammary cancer model

Msaki, A., Pastò, A., Curtarello, M., Arigoni, M., Barutello, G., Calogero, R., Macagno, M., Cavallo, F., Amadori, A., & Indraccolo, S. (2016) · Oncotarget · doi:10.18632/oncotarget.8859 · Cited by 18 · see citing works

Prognostic Significance of High VEGF-C Expression for Patients with Breast Cancer: An Update Meta Analysis

Zhang, Z., Luo, G., Tang, H., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165725 · Cited by 18 · see citing works

Glucose-dependent growth arrest of leukemia cells by MCT1 inhibition: Feeding Warburg’s sweet tooth and blocking acid export as an anticancer strategy

Pivovarova, A. I., & MacGregor, G. G. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.12.048 · Cited by 17 · see citing works

The Clinicopathologic and Prognostic Value of Hypoxia-Inducible Factor-2α in Cancer Patients: A Systematic Review and Meta-Analysis

Luo, D., Liu, H., Lin, D., Lian, K., & Ren, H. (2018) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-0881 · Cited by 17 · see citing works

A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial

Karn, T., Meißner, T., Weber, K. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1954 · Cited by 16 · see citing works

Diffuse optical spectroscopy for monitoring the responses of patients with breast cancer to neoadjuvant chemotherapy

Liu, Y. H., Xue, L. B., Yang, Y. F., et al. (2018) · Medicine · doi:10.1097/md.0000000000012683 · Cited by 13 · see citing works

HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells

Lee, S.-H., Golinska, M., & Griffiths, J. R. (2021) · Cells · doi:10.3390/cells10092371 · Cited by 169 · see citing works

HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy

Salman, S., Meyers, D. J., Wicks, E. E., Lee, S. N., Datan, E., Thomas, A. M., Anders, N. M., Hwang, Y., Lyu, Y., Yang, Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156774 · Cited by 111 · see citing works

Cancer-on-chip models for metastasis: importance of the tumor microenvironment

Jouybar, M., de Winde, C. M., Wolf, K., Friedl, P., Mebius, R. E., & den Toonder, J. M. J. (2024) · Trends in Biotechnology · doi:10.1016/j.tibtech.2023.10.001 · Cited by 66 · see citing works

Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression

McCubrey, J. A., Yang, L. V., Abrams, S. L., Steelman, L. S., Follo, M. Y., Cocco, L., Ratti, S., Martelli, A. M., Augello, G., & Cervello, M. (2022) · Cells · doi:10.3390/cells11142155 · Cited by 49 · see citing works

Sunitinib lipid nanoparticles remodel tumor vasculature to synergize with two-stage radiotherapy for enhanced radiosensitivity in breast Cancer

Li, P., Dong, Z., Jiang, Q., Yu, C., Liu, Y., Yuan, R., Qiu, Y., Meng, T., Hu, F., & Yuan, H. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114406 · Cited by 6 · see citing works

The vasohibin family: a novel family for angiogenesis regulation

Sato, Y. (2012) · The Journal of Biochemistry · doi:10.1093/jb/mvs128 · Cited by 111 · see citing works

The vasohibin family: Novel regulators of angiogenesis

Sato, Y. (2012) · Vascular Pharmacology · doi:10.1016/j.vph.2012.01.002 · Cited by 28 · see citing works

A PlGF-1 Derived Peptide Inhibits Angiogenesis via HIF-1β/VEGF Pathway

Wang, W., Gu, Q., Xu, X., et al. (2016) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-016-9567-z

A novel in vitro angiogenesis model based on a microfluidic device

Dai, Xiao-zhen, Cai, et al. (2011) · 中国科学通报：英文版 · Cited by 8 · see citing works

SAT-179 A UNIQUE DISTRIBUTION OF HYPOXIA-INDUCIBLE FACTOR IN CULTURED TUBULAR CELLS IN HYPOPERFUSION MODEL

Hirakawa, Y., Honda, T., Tanaka, T., et al. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.02.191